Anti‐SARS‐CoV‐2 Antibodies in Long‐COVID—Markers of Protection or Elevated Risk? A Systematic Review DOI Open Access
Sylvia Mink,

F.X. Wilhelm,

Janne Cadamuro

et al.

Reviews in Medical Virology, Journal Year: 2025, Volume and Issue: 35(2)

Published: Feb. 24, 2025

Long-COVID affects a significant number of COVID-19 survivors, profoundly impacting daily life and work. Although research suggests potential link between antibody levels long-COVID risk, findings remain inconclusive. Understanding dynamics could support the identification patients at improve diagnosis, guide protective strategies such as vaccination. Despite growing evidence, no systematic review has yet evaluated current literature on this topic. We therefore aimed to synthesise evaluate existing evidence association anti-SARS-CoV-2 titres long-COVID, with goal clarifying their role in predicting guiding patient management, informing future directions. Studies published PubMed/Medline databases January 2020 October 2024 were included without language restrictions. body fluids other than serum/blood excluded. Study selection quality assessment was conducted independently by two researchers. After screening 949 studies, 58 studies encompassing 53,739 individuals, 7812 patients, included. Evidence highly heterogenous but most reported an anti-SARS-CoV-2-spike antibodies although nature appeared be dependent time from acute infection. Low during associated increased risk long-COVID. The low that maintaining sufficiently high may protective. However, level is further sufficient power are required confirm potentially determine cutoffs.

Language: Английский

Anti‐SARS‐CoV‐2 Antibodies in Long‐COVID—Markers of Protection or Elevated Risk? A Systematic Review DOI Open Access
Sylvia Mink,

F.X. Wilhelm,

Janne Cadamuro

et al.

Reviews in Medical Virology, Journal Year: 2025, Volume and Issue: 35(2)

Published: Feb. 24, 2025

Long-COVID affects a significant number of COVID-19 survivors, profoundly impacting daily life and work. Although research suggests potential link between antibody levels long-COVID risk, findings remain inconclusive. Understanding dynamics could support the identification patients at improve diagnosis, guide protective strategies such as vaccination. Despite growing evidence, no systematic review has yet evaluated current literature on this topic. We therefore aimed to synthesise evaluate existing evidence association anti-SARS-CoV-2 titres long-COVID, with goal clarifying their role in predicting guiding patient management, informing future directions. Studies published PubMed/Medline databases January 2020 October 2024 were included without language restrictions. body fluids other than serum/blood excluded. Study selection quality assessment was conducted independently by two researchers. After screening 949 studies, 58 studies encompassing 53,739 individuals, 7812 patients, included. Evidence highly heterogenous but most reported an anti-SARS-CoV-2-spike antibodies although nature appeared be dependent time from acute infection. Low during associated increased risk long-COVID. The low that maintaining sufficiently high may protective. However, level is further sufficient power are required confirm potentially determine cutoffs.

Language: Английский

Citations

0